Bernstein Names Top Biotech Stock Pick: Vertex Leads After Rival Drug Fails

Biotechnology firm Vertex Pharmaceuticals (VRTX) has been named the top stock pick by analyst Jeffrey Walch of Bernstein, following the failure of a competing drug trial. The setback affects rival Sionna, which reported negative results from its PreciSION CF phase 2a trial of SION-719, when combined with Vertex's Trikafta. The trial failed to meet its key activity endpoint, showing only a -1.0 mmol/L mean placebo-adjusted sweat chloride change (p=0.7), significantly below the required 10 mmol/L improvement.

This result eliminates a major competitive threat to Vertex's dominant cystic fibrosis treatment, Trikafta. Walch maintains that Vertex's leadership in this market is likely to remain unchallenged for the foreseeable future, as competitors will need to surpass Vertex's therapy, Alyftrek, to gain ground. The analyst believes Vertex's expertise in drug development and ample time will enable the company to develop its own next-generation treatment to extend its market leadership well beyond the current exclusivity period for Alyftrek, which ends around 2038.